ogram Patient Enrollment Expected
Selected Abstract
MGI PHARMA Announces Initiation of Aquavan(R) Injection Pivotal Program; Patient Enrollment Expected To Conclude By Year-End.
MINNEAPOLIS -- MGI PHARMA, INC. (Nasdaq:MOGN), an oncology- and acute care- focused biopharmaceutical company, today announced the initiation of the Aquavan(R) (fospropofol disodium) Injection pivotal program. This program consists of two randomized, double blind, multicenter phase 3 trials and an ... March 20, 2006; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
